辅助生殖技术受孕早期低β-hCG妊娠中M4模型预测异位妊娠的表现
这项前瞻性队列研究纳入243例辅助生殖技术受孕、孕4+0至4+2周β-hCG为5-50 IU/L的妊娠,评估M4模型分类异位妊娠风险的表现。M4模型检测高风险妊娠的敏感度为60.0%(95%CI 43.6-74.4%),特异度为79.8%(95%CI 73.8-84.7%),AUC为0.72(95%CI 0.62-0.81)。结论认为M4模型在此类妊娠中分类能力有限,不推荐使用;此类妊娠宫内活产概率低且早期流产率高。
要点
- M4模型对ART受孕低β-hCG妊娠的EP高风险分类敏感度60.0%、特异度79.8%。
- M4模型AUC为0.72,与最终诊断一致性低(kappa=0.30)。
- 243例中仅47例(19.3%)为IUP,其中一半早期流产,仅9.5%继续妊娠。
核心结论
- M4模型在ART受孕早期低β-hCG妊娠中区分EP高风险与低风险的能力有限,不推荐在该人群中使用。
- 未观察到与M4模型应用直接相关的严重不良事件。
- 此类妊娠最终为IUP的概率低,且早期流产率高。
研究设计与样本
- 前瞻性队列研究,纳入243例经辅助生殖技术受孕、孕4+0至4+2周β-hCG为5-50 IU/L的妊娠。
- 48小时后复查β-hCG,按M4模型分为高风险( probable EP/PPUL,EP风险≥5%)、低风险 probable IUP、低风险 probable FPUL。
- 以孕11-13周最终妊娠结局(EP/PPUL、FPUL或IUP)为参考评估预测性能。
主要发现
- M4模型检测高风险妊娠(EP/PPUL)的敏感度为60.0%(95%CI 43.6-74.4%),特异度为79.8%(95%CI 73.8-84.7%)。
- M4模型区分高风险与低风险(FPUL/IUP)的AUC为0.72(95%CI 0.62-0.81)。
- 阳性似然比为2.97(95%CI 2.03-4.36),阴性似然比为0.50(95%CI 0.33-0.76)。
- 模型分类与最终诊断的kappa指数为0.30(95%CI 0.16-0.43),一致性低。
- 14例最终高风险妊娠最初被M4模型判为低风险,其中7例期待管理、5例甲氨蝶呤(MTX)治疗、2例需腹腔镜手术。
关键数值与推荐
- M4模型高风险判定阈值:EP风险≥5%。
- 低风险 probable IUP:EP风险<5%且IUP可能性大于FPUL。
- 低风险 probable FPUL:EP风险<5%且FPUL可能性大于IUP。
临床怎么用
- 不推荐将M4模型用于ART受孕早期低β-hCG妊娠的EP风险分类。
- 对此类妊娠应告知IUP概率低(19.3%)且早期流产率高,需密切随访。
- 应用M4模型未直接导致严重不良事件,但存在将高风险妊娠误判为低风险的情况。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the safety and performance of the M4 model for classifying as high risk or low risk for ectopic pregnancy (EP) pregnancies conceived by assisted reproductive technologies (ART) that present with low beta-human chorionic gonadotropin (β-hCG) concentration in early gestation. METHODS: This was a prospective cohort study of 243 pregnancies conceived by ART with low β-hCG levels (5-50 IU/L) at 4 + 0 to 4 + 2 weeks' gestation. After subsequent β-hCG testing at 48 h, pregnancies were classified according to the M4 model into the following categories: (i) high risk, probable EP/persistent pregnancy of unknown location (PPUL), when the risk for EP was ≥ 5%; (ii) low risk, probable intrauterine pregnancy (IUP), when the risk of EP was < 5% and the likelihood of IUP was greater than that of a failed pregnancy of unknown location (FPUL); and (iii) low risk, probable FPUL, when the risk of EP was < 5% and the likelihood of a FPUL was greater than that of an IUP. The predictive performance of the M4 model for EP and its ability to discriminate between high- and low-risk pregnancies was assessed using the final pregnancy outcome at 11 to 13 weeks of gestation as reference, which was classified as EP/PPUL, FPUL or IUP. RESULTS: The sensitivity and specificity of the M4 model in detecting a high-risk pregnancy (EP/PPUL) were 60.0% (95% CI, 43.6-74.4%) and 79.8% (95% CI, 73.8-84.7%), respectively. The area under the receiver-operating-characteristics curve of the M4 model for discriminating between high-risk and low-risk (FPUL/IUI) pregnancies was 0.72 (95% CI, 0.62-0.81). The model had a positive likelihood ratio of 2.97 (95% CI, 2.03-4.36) and a negative likelihood ratio of 0.50 (95% CI, 0.33-0.76). The kappa index was 0.30 (95% CI, 0.16-0.43), indicating a low degree of agreement between the model classification and the final diagnosis. No serious adverse events related directly to the application of the M4 model were observed, although 14 pregnancies classified ultimately as high risk had been categorized initially as low risk by the M4 model. Of these, seven resolved with expectant management, five with methotrexate (MTX) and two required laparoscopic surgery (one after failure of medical treatment with MTX and one after deviation from the follow-up protocol). There were no cases of EP/PPUL with additional complications or need for blood or other blood product transfusion. Of the 243 ART pregnancies with low β-hCG concentration in early gestation, only 47 (19.3%) had an IUP, half (24/47) of which had an early miscarriage, resulting in only 9.5% (23/243) cases having an ongoing pregnancy. CONCLUSIONS: Application of the M4 model in pregnancies conceived by ART with low β-hCG concentration in early gestation showed limited capacity in classifying them as being at low or high risk for EP, therefore, its use in pregnancies of this type is not recommended. No serious adverse events or complications related to the use of the model were observed. These pregnancies have a low probability of ending in an IUP as well as a high rate of early miscarriage. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Valdera Simbrón CJ, Hernández Rodríguez C, Llanos Jiménez L, et al. Management of early gestations with low beta-human chorionic gonadotropin conceived by assisted reproductive technologies: performance of M4 predictive model. Ultrasound Obstet Gynecol. 2021. PMID: 33656199. doi:10.1002/uog.23625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。